Administration of a topical TRPV1 antagonist markedly reduced scratching behavior, as well as erythema and edema, in atopic dermatitis mice models by day 12 of treatment, a finding previously supported by other murine studies [34,35]. The gene discussed is TRPV1; the disease is atopic eczema.